Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Tinlarebant in Adolescent Stargardt Disease
2024-513483-26-00Phase 3Completed
- Sponsor
- Belite Bio, Inc
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Fundus Flavimaculatus (FF) comparing Tinlarebant with Placebo (2 arms). Primary endpoint: Annualized rate of lesion growth in aggregate area of atrophy (DDAF). Started May 2024; status: completed.
02
Drugs
tinlarebant
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on 2024-513483-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513483-26-00.